Holen Sie sich die Stockscreener-App
6.52
3.99%
0.25
Vorhandelsmarkt:
6.63
0.11
+1.69%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.27
Offen:
$6.285
24-Stunden-Volumen:
1.37M
Relative Volume:
0.47
Marktkapitalisierung:
$297.81M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-7.8554
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
-9.13%
1M Leistung:
-21.07%
6M Leistung:
-56.24%
1J Leistung:
+35.83%
1-Tages-Spanne:
$6.24
$6.78
1-Wochen-Bereich:
$6.19
$7.45
52-Wochen-Spanne:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.52 | 327.95M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Is Capricor Therapeutics Inc. a good long term investmentBreakthrough stock performance - Autocar Professional
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsCAPR - The Globe and Mail
ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Capricor Therapeutics Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Behind Capricor Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
What analysts say about Capricor Therapeutics Inc. stockTriple-digit growth rates - jammulinksnews.com
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 15% loss last week hit both individual investors who own 47% as well as institutions - simplywall.st
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
What drives Capricor Therapeutics Inc. stock priceBreakout portfolio performance - Autocar Professional
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - ETX View
(CAPR) Technical Data - news.stocktradersdaily.com
Securities Fraud and Market Volatility in Biotech: Lessons from Capricor's Downfall - AInvest
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025Capricor Therapeutics, Inc. (CAPR) - TradingView
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigatin - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shareholders of Class Action Lawsuit and September 15, 2025 Deadline - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - StreetInsider
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Capricor Therapeutics, Inc.September 15, 2025 Deadline - ACCESS Newswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: - GlobeNewswire
Investor Sues Biotech Capricor After Product's FDA Denial - Law360
Levi & Korsinsky Urges Capricor Therapeutics, Inc. (CAPR) Shareholders to Act Before Lead Plaintiff Deadline September 15, 2025 - ACCESS Newswire
Capricor Investor Sues After Disappointing FDA Return on Therapy - Bloomberg Law News
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - TradingView
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Will Capricor Therapeutics Inc. stock split in the near futureInvestor Favorite Picks - Newser
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewswire
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors - TradingView
Capricor’s Trial Data Deception Triggers Major Lawsuit - TipRanks
What analysts say about Capricor Therapeutics Inc. stock outlookPrecision Entry Strategy - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
Shareholders Filed a Lawsuit Against Capricor for Misleading Investors About FDA Approval - TradingView
Capricor Therapeutics ($CAPR) Regulatory Misrepresentations and Stock Collapse Case - TradingView
BREAKING: Capricor Therapeutics Sued For Securities Fraud; - GlobeNewswire
September 15, 2025 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):